Suchergebnisse - "Olkus, Alexander"

PubPharm (11)

1

Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer : An Exploratory Analysis of Real-World Data

enthalten in: Targeted oncology | 2024

von Olkus, A. | Tomczak, A. | Berger, A. | +13

2

Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data

enthalten in: Targeted oncology | 2024

von Olkus, A. | Tomczak, A. | Berger, A. | +13

3

Treating hepatitis D with bulevirtide - Real-world experience from 114 patients

enthalten in: JHEP reports : innovation in hepatology | 2023

von Dietz-Fricke, C. | Tacke, F. | Zöllner, C. | +39

4

Treating hepatitis D with bulevirtide : real-world experience from 114 patients

enthalten in: JHEP reports | April 2023

von Dietz-Fricke, C. | Tacke, F. | Zöllner, C. | +39

5

Author Correction : Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

enthalten in: Nature medicine | 2022

von Malehmir, M. | Pfister, D. | Gallage, S. | +64

ErratumFor: Nat Med. 2019 Apr;25(4):641-655. - PMID 30936549

6

Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma : drawbacks and opportunities

enthalten in: Journal of cancer research and clinical oncology | 2021

von Wehling, C. | Dill, M. | Olkus, A. | +11

7

Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities

enthalten in: Journal of cancer research and clinical oncology | 2021

von Wehling, C. | Dill, M. | Olkus, A. | +11

8

Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities

enthalten in: Journal of cancer research and clinical oncology | 2021

von Wehling, C. | Dill, M. | Olkus, A. | +11

9

Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities

enthalten in: Journal of cancer research and clinical oncology | 2021

von Wehling, C. | Dill, M. | Olkus, A. | +11

10

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

enthalten in: Nature medicine | 2019

von Malehmir, M. | Pfister, D. | Gallage, S. | +64

CommentIn: Nat Rev Cancer. 2019 Jun;19(6):302. - PMID 31036885